# Baikui Rui Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/baikui-rui-bio

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Total disclosed funding: $7.9M
- Latest round: Seed (Feb 17, 2022)
- Investors on record: 4

## About

Based in Shenzhen, China, and founded in 2021, Baikui Rui Bio, a.k.a. Baikuray Biotech operates as a synthetic biology company that develops antibiotic resistance biosynthesis. In February 2022, Baikui Rui Bio raised CNY 50 million in seed funding led by Genesis Capital, with participation from Bio Venture, CASH Capital, Shenzhen Angel Investment Guiding Fund, and Xiamen Fengxue.

Baikui Rui Bio provides antibiotic resistance biosynthesis products, such as biopesticides, bactericidal proteins, and functional peptides.

Baikui Rui Bio plans to use its proceeds from February 2022 to biosynthesis its products such as targeted bactericidal proteins and functional peptides, hire more talents, market expansion, establish the first phase of the industry Chemical production base, and accelerate the product layout of biopesticides in the fields of rare metabolic diseases, pet intestinal health, and functional skin health.

## Funding rounds

- Seed, Feb 17, 2022, $7.9M — CASH Capital, YuanBio Venture, Genesis Capital, Shenzhen Investment Control Capital

## Investors

- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Seed
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Seed
- Genesis Capital — Seed
- Shenzhen Investment Control Capital (https://capitalatlas.ai/funds/shenzhen-investment-control-capital) — Seed